SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-121818
Filing Date
2024-11-06
Accepted
2024-11-06 07:43:01
Documents
63
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tngx-20240930.htm   iXBRL 10-Q 1748386
2 EX-31.1 tngx-ex31_1.htm EX-31.1 16804
3 EX-31.2 tngx-ex31_2.htm EX-31.2 16749
4 EX-32.1 tngx-ex32_1.htm EX-32.1 8094
5 EX-32.2 tngx-ex32_2.htm EX-32.2 8085
  Complete submission text file 0000950170-24-121818.txt   6810214

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tngx-20240930.xsd EX-101.SCH 935035
66 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20240930_htm.xml XML 1148867
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39485 | Film No.: 241429266
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)